Skip to main content

Table 1 Baseline characteristics in colorectal cancer patients and control subjects

From: Interplay between 3′-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans

Characteristics

Control

CC

OR (95% CI)

p

RC

OR (95% CI)

p

N

400

264

  

186

  

Age (mean±SD)

60.89 ± 11.72

61.85 ± 12.85

1.01 (0.99 - 1.02)

0.320

62.33 ± 11.46

1.01 (1.00 - 1.03)

0.165

Gender (male), n (%)

170 (42.5)

124 (47.0)

1.20 (0.88 - 1.64)

0.257

88 (47.3)

1.21 (0.86 - 1.72)

0.275

Metabolic syndrome, n (%)

95 (23.8)

98 (37.1)

1.90 (1.35 - 2.66)

<.001

73 (39.2)

2.07 (1.43 - 3.01)

<.001

Anti-HTN drug or BP ≥ 130/85 mmHg, n (%)

157 (39.3)

159 (60.2)

2.34 (1.71 - 3.22)

<.001

120 (64.5)

2.81 (1.96 - 4.04)

<.001

Anti-DM drug or FBS ≥ 100 mg/dl, n (%)

166 (41.5)

149 (56.4)

1.83 (1.33 - 2.50)

<.001

104 (55.9)

1.79 (1.26 - 2.54)

0.001

TG ≥ 150 mg/dl, n (%)

135 (33.8)

67 (25.4)

0.67 (0.47 - 0.94)

0.022

46 (24.7)

0.65 (0.44 - 0.95)

0.029

BMI ≥ 25 kg/m2, n (%)

93 (23.3)

65 (24.6)

1.08 (0.75 - 1.55)

0.685

51 (27.4)

1.25 (0.84 - 1.85)

0.276

HDL-C < 40(male)/50(female) mg/dl, n (%)

78 (19.5)

113 (42.8)

3.09 (2.18 - 4.37)

<.001

84 (45.2)

3.40 (2.32 - 4.97)

<.001

Tumor size

       

<5 cm

-

94 (35.6)

-

-

87 (46.8)

-

-

≥5 cm

-

170 (64.4)

-

-

99 (53.2)

-

-

TNM stage, n (%)

       

I

-

22 (8.3)

-

-

20 (10.8)

-

-

II

-

118 (44.7)

-

-

71 (38.2)

-

-

III

-

94 (35.6)

-

-

79 (42.5)

-

-

IV

-

30 (11.4)

-

-

16 (8.6)

-

-

  1. Colon cancer (CC), Rectal cancer (RC), Odds ratio (OR), Confidence interval (CI), Standard deviation (SD), Blood pressure (BP), Fasting blood sugar (FBS), Hypertension (HTN), Diabetes mellitus (DM), Triglycerides (TG), Body mass index (BMI), High density lipoprotein-cholesterol (HDL-C), Tumor node metastasis (TNM). ORs and p values were calculated by univariate logistic regression.